Introduction:
Recently, telomeres have become an attractive target for anticancer therapeutics due to nearuniversal overexpression of telomerase in tumors, which endows malignant cells with immortality (Crees et al., 2014, Ruden and . Guanine-rich oligonucleotides (GROs), including single-stranded (SS) telomere homolog oligonucleotides, are known to have potent anti-cancer effects when administered to several malignant cell types both in vitro and in vivo (Crees et al. 2014) . Previous studies have shown that increasing the stability of telomeric Gquadruplexes (G4), 4-stranded DNA secondary structures stabilized by the sequential stacking of guanine quartets in a planar arrangement, using exogenous G4-stabilizing ligands induces dissociation of telomere associated proteins TRF2 and POT1, which are critical for telomere stability (Gomez et al., 2006 , Tahara et al., 2006 . Growing evidence shows that G4 formation can stall the replication fork during DNA synthesis and inhibit telomere replication by preventing telomerase from binding to the telomere (Crees et al., 2014 , Maizels, 2006 . Therefore, further studies are required to understand the anti-cancer effects of GROs and the role of telomere associated proteins in their mechanism of action.
One particularly well-studied 11-base T-oligo (dGTTAGGGTTAG), which is homologous to the 3'-telomere overhang sequence, induces potent DNA damage responses (DDRs) in several cancers (Eller et al., 2002 , Puri et al., 2004 , Puri et al., 2014 , Ruden and Puri, 2013 , Yaar et al., 2007 and has minimal or no toxicity on normal cells (Puri et al., 2004 , Puri et al., 2014 . T-oligo is also known to induce enhanced melanogenesis and also decreases chronic photo-damage to human skin by increasing DNA repair after UV radiation (Arad et al., 2006) . Moreover, T-oligo is a powerful modulator of pigmentation and growth of organ cultured 4 human scalp hair follicles further emphasizing its role in the field of dermatology (Hadshiew et al., 2008) . Our earlier studies indicated that SS-T-oligo may possibly recruit the shelterin complex, a group of six proteins regulating telomeric stability and homeostasis, away from the telomere, uncapping the telomere overhang and causing DDRs (Pitman et al., 2013) . GROs such as T-oligo can also form G-quadruplexes (G4) (Crees et al., 2014 , Rankin et al., 2013 , Ruden and Puri, 2013 and some evidence suggests that G4 formation by GROs may mediate DDRs presumably by altering telomere architecture (Crees et al., 2014 , Rankin et al., 2013 . However, the functional roles of these secondary structures in inducing DDRs have not been thoroughly described. Currently, there is no clear correlation between G4 formation and anti-cancer activity of GROs in terms of secondary structures (Page et al., 1999) . Therefore, it is important to study G4 forming capabilities of GROs such as T-oligo to improve their design for cancer therapy.
Further studies are required to understand the anti-cancer effects of T-oligo including their relation to telomeres and potential use in melanoma treatment.
The purpose of this study was to determine the G-quadruplex forming potential of an oligonucleotide homologous to the telomere overhang, T-oligo, using nuclear magnetic resonance (NMR), the gold standard in G4 detection (Adrian et al., 2012) . G4 formation by Toligo was also investigated inside the nucleus of melanoma cells using an antibody which detects G-quadruplexes. We also show that the anticancer signaling mechanism of T-oligo involves human telomerase reverse transcriptase (hTERT) and JNK which further suggests that T-oligo induces DDR signals through inhibition of telomerase and telomere associated proteins.
Results:

Detection of G4-T-oligo by non-denaturing-PAGE and NMR
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The G4 structures were verified by loading 0.1μg of the SS-T-oligo and G4-T-oligo into a 20% polyacrylamide gel under non-denaturing conditions. G4 formation by T-oligo was enhanced in the presence of 500mM KCl (Figure 1a) , while the same concentration of NaCl produced negligible G4 content (Figure 1b) . The extent of G4 formation depends significantly on the concentration of T-oligo present during thermal denaturation, which is expected for G4 formation since four strands must come together to form one complex (Figure 1c) . Hence, increasing concentration of SS-T-oligo favors formation of more G4. NMR studies for T-oligo in KCl showed the presence of downfield imino proton resonances (9-14 ppm) which confirmed that T-oligo forms G4 structures (Figure 1d ). These resonances were absent in NaCl (Figure 1e ), which was consistent with non-denaturing PAGE experiments showing negligible G4 in NaCl.
Confirmation of G-quadruplex formation by T-oligo inside nucleus of melanoma cells
To confirm G4 formation by T-oligo, we used a specific G4 detecting antibody (BG4) (Biffi et al. 2013) . Immunofluorescence studies using FITC-T-oligo and BG4 antibody confirmed the 
Anti-proliferative activity, resistance to nuclease activity and cellular uptake of SS-T-oligo and G4-T-oligo
The stability of G4 was examined by incubating G4 with DNase I for different time periods. G4-T-oligo partially resisted nuclease degradation by DNase I up to 90min (Figure 3a ).
Densitometry analysis after nuclease digestion demonstrated a 52.6% decrease in T-oligo and a 6 20% decrease in G4-T-oligo with a 96% increase in single-stranded free T-oligo in the G4-Toligo sample after 90min of DNase I treatment (Figure 3a) . These results indicate that G4-Toligo is more resistant to nuclease treatment compared to SS-T-oligo and can be converted into SS-T-oligo. Further, the results of anti-proliferative activity of SS-T-oligo and G4-T-oligo showed that G4-T-oligo was less effective (27.1-32.4%) than SS-T-oligo (42.8-61.6%) in inhibiting melanoma cell proliferation as observed after MTT assay (Figure 3b ). However, both SS-T-oligo and G4-T-oligo had comparable cellular uptake as measured by FACS analysis (Figure 3c ). This suggests that the reduced anti-proliferative activity of G4-T-oligo is not likely attributed to poor cellular uptake. This phenomenon could be due to reduction of single-stranded T-oligo in G4 form and its ability to bind TRF2 and POT1 as described in the next section.
Interaction of T-oligo with telomere associated proteins TRF2 and POT1
Densitometry analysis after western blotting showed that T-oligo treatment upregulated TRF2 by 2.2 and 3.0-fold (p<0.01) at 48h and 72h, respectively, and POT1 by 3.0-fold (p<0.02) both at 48 and 72h in melanoma cells (Figure 4a-4d) , which may be a response to uncapped telomeres induced by T-oligo (Karlseder et al., 1999) and corroborates well with the hypothesis that Toligo induces telomere dysfunction. Immunofluorescence studies confirmed upregulation of TRF2 (2.4-fold) and POT1 (2.0-fold) following treatment with T-oligo ( Figure 4g ). Following administration, T-oligo rapidly enters into the nucleus in melanoma cells. However, whether or not T-oligo binds to or associates with the telomere or its components is currently unknown. The predominant bands of TRF2 and POT1 in western blot analysis of melanoma cell lysates after pull-down assay using T-oligo and streptavidin magnetic beads showed that T-oligo indeed interacted with these telomeric proteins (Fig 4e and f) .
Anti-proliferative effects of T-oligo through JNK
Western blot analysis showed upregulation of both p-JNK and total JNK by 4.0-and 2.0-fold respectively, at 24h in T-oligo treated melanoma cells (Figure 5a ). JNK, an inducer of apoptosis, has previously been demonstrated to be activated by G4 stabilizing ligands causing telomere dysfunction (Rankin et al., 2013) . To further confirm the involvement of p-JNK in T-oligomediated apoptosis, we used a specific JNK inhibitor SP600125. Western blot analysis showed that T-oligo mediated upregulation of p-JNK was reversed in presence of SP600125 ( Figure 5b ).
The MTT assay results showed a 73.8% decrease in cell viability after 96h of T-oligo treatment alone in melanoma cells; however, cell viability was decreased to 71.8%, 55.2%, 45.8%, and 25.3% when SP600125 was present in concentrations of 4μM, 8μM, 10μM, and 12μM, respectively, compared to diluent ( Figure 5c ). Treatment with SP600125 alone had minimal effect on cell proliferation. These results show that the inhibition of JNK by SP600125 reversed the anti-proliferative activity of T-oligo in a dose-dependent manner.
Downregulation of hTERT expression by T-oligo
To investigate the role of hTERT in T-oligo-induced melanoma cell death, the mRNA expression of hTERT was assessed using qRT-PCR. The mRNA expression of hTERT was decreased by 50% after treatment with T-oligo in melanoma cells (Figure 5d ). Since T-oligo increased JNK phosphorylation, it was speculated that the JNK pathway may be involved in T-oligo-mediated hTERT downregulation. To test this hypothesis, we investigated the effect of the JNK inhibitor SP600125 on hTERT expression in T-oligo treated MM-AN cells. Treatment with 12μM SP600125 in presence of T-oligo partially reversed the downregulation of hTERT since we 8 observed only 16% decrease in hTERT expression in comparison to 50% reduction by T-oligo treatment alone. SP600125 alone had no effect on hTERT expression (Figure 5d ). The results suggest that activation of JNK may be required for hTERT downregulation by T-oligo in melanoma cells.
Discussion:
The incidence of malignant melanoma has increased significantly during the past decade (Puri et al., 2007 , Siegel et al. 2016 ). Metastatic melanoma is very challenging to treat as it is highly resistant to chemotherapy and is almost always fatal (Puri et al. 2004 ). Telomeres and telomerase have become popular targets for cancer therapeutics due to their involvement in the development of immortality in nearly 85-90% of all cancers (Cookson and Laughton, 2009, Ruden and . A study by Eller et al demonstrated that thymidine dinucleotides (pTpT) and other oligonucleotides could mimic cellular responses to UV irradiation including enhanced melanogenesis (Eller et al., 1994) . Further studies using an oligonucleotide homologous to the telomere overhang called T-oligo (5'-GTTAGGGTTAG-3') have been shown to induce potent DNA damage responses (DDRs) in several cancers, including melanoma (Eller et al., 2002 , Puri et al., 2004 , Rankin et al., 2008 , Yaar et al., 2007 .
In this study, we demonstrate that T-oligo forms stable, 4-stranded intermolecular G-quadruplex structures in vitro in presence of KCl using one dimensional NMR spectra, as well as nondenaturing PAGE. The downfield imino proton resonances (9-14 ppm) obtained in the NMR data for G-quadruplexes correspond to each Guanine residue that is exchanging protons with the solution at a particular frequency. The G-quadruplex formation by T-oligo was observed to be highly dependent on strand concentration as confirmed using non-denaturing PAGE and suggest the fourth order molecularity of a tetramolecular G-quadruplex (Mergny et al., 2005) . Further, to examine the G-quadruplex formation by T-oligo, that may occur inside the cellular environment after internalization, a specific anti-G-quadruplex antibody (BG4) (Biffi et al., 2013) was utilized. Immunofluorescent foci specific to G-quadruplex structures after treatment with FITC-T-oligo were observed inside the nuclei of melanoma cells. These results suggest that T-oligo may spontaneously adopt a G-quadruplex structure at physiologic conditions inside the cells.
Further, when MM-AN cells were treated with G4-T-oligo, its anti-proliferative activity was significantly reduced compared to its single-stranded counterpart which showed higher antiproliferative effects in a dose-dependent manner. In contrast, there was no dose-dependent increase in anti-proliferative activity of G4-T-oligo. However, FACS analysis demonstrated that cellular uptake between SS-T-oligo and G4-T-oligo was comparable, suggesting that the reduced anti-proliferative activity of G4-T-oligo was not attributed to differences in cellular uptake. One possible explanation for the reduced anti-proliferative activity of G4-T-oligo may be that intermolecular G-quadruplex formation effectively reduces strand concentration compared to single-stranded species, thereby reducing the number of strands that can elicit anticancer responses. The single-stranded T-oligo may also bind more effectively to TRF2 and POT1
inducing DNA damage and cell death which is reduced in the case of G4-T-oligo. Moreover, G4-T-oligo was found to be more stable after DNase I digestion than SS-T-oligo and can be converted into SS-T-oligo by DNase I. G-quadruplex stability may further prohibit interaction between endogenous cell components (e.g. telomeric proteins) through steric interference.
To further investigate cellular mediators that facilitate T-oligo-induced cytotoxicity, we examined expression levels of SAPK/JNK, TRF2 and POT1 proteins following T-oligo administration in melanoma cells. Upregulation of SAPK/JNK, POT1 and TRF2 supports evidence that T-oligo may induce telomere dysfunction, since upregulation of these proteins occurs following DNA damage responses (Klapper et al., 2003) and may mediate telomere overhang disruption caused by G-quadruplex stabilizing ligands (Mikami-Terao et al., 2008) .
Moreover, it has been shown that T-oligo induces γH2AX foci, a marker of DNA damage, and that these foci co-localized with telomeres (Eller et al., 2006) . Proteins involved in DNA doublestrand break recognition and repair may play active roles in the cellular response to damaged or dysfunctional telomeric structures, and TRF2 has been reported to bind to several of these proteins, including the Rad50-MRE11-NBS1 complex (Zhu et al., 2000) , ATM (Karlsederet al., 1999) , and helicases WRN and BLM (Opresko et al., 2002) . Molecular defects that inhibit the resolution of the intermediates can lead to TRF2 accumulation (Nijjar et al., 2005) . Our pulldown assay showed predominant bands of TRF2 and POT1 proteins in biotinylated-T-oligo treated melanoma cell lysates. It may be possible that TRF2 and POT1, which are known to bind to telomeric structures, also bind to T-oligo within the cell, inhibiting free TRF2 and POT1 from binding and leading to its accumulation.
Additionally, T-oligo induced activation of SAPK/JNK in melanoma cells, corroborating previous studies performed in ovarian and lung cancer, which demonstrated JNK activation by an intramolecular G-quadruplex-forming GRO (Rankin et al., 2013, Sarkar and .
This was further confirmed using a specific JNK inhibitor SP600125, which diminished T-oligo mediated JNK phosphorylation. Further, in cell proliferation assays, treatment of SP600125 with T-oligo in melanoma cells partially reversed the anti-proliferative activity of T-oligo. Most malignant cells have high telomerase activity, but in the majority of somatic cells it is barely detectable. Expression of hTERT, a catalytic subunit of telomerase, has been correlated with telomerase activity in cancer cells. Importantly, T-oligo also inhibited hTERT expression in melanoma cells. It has been suggested that JNK activation may lead to downregulation of hTERT (Tian et al., 2015) . Thus, T-oligo's anti-proliferative activity could also be mediated through downregulation of hTERT via the activation of JNK pathway.
In conclusion, we demonstrate that T-oligo forms tetrameric intermolecular G-quadruplexes in vitro and also inside the cells which can be detected by BG4. This study also demonstrates that two GROs of the same sequence, but different secondary structures (single-stranded and Gquadruplex), have significantly different cytotoxic activity, indicating an important structurefunction relationship that could influence the design of future anticancer GROs. Furthermore, by showing the upregulation of shelterin proteins TRF2 and POT1 after T-oligo treatment, and pulldown assay using biotinylated T-oligo, we provide evidence that T-oligo interacts with the telomere and its associated proteins causing telomere dysfunction in melanoma cells. It may also be possible that specific shelterin proteins dissociate from the telomere and bind to T-oligo, and thus melanoma cells produce more TRF2 and POT1 in an attempt to reverse telomere exposure.
This study is an important step forward in understanding the anticancer effects of GROs, and their relationship to secondary structures. Moreover, we also show that proteins inducing DDRs such as SAPK/JNK are activated following T-oligo treatment leading to inhibition of hTERT expression in melanoma cells, providing insights into the mechanisms underlying T-oligo's anticancer activity. Hence, this study opens avenues for future investigations and improvements in potential GRO therapies.
Materials and Methods: Oligonucleotides
Oligonucleotides homologous (5'-dGTTAGGGTTAG-3', "T11", and 5'-dTGGGATTGGGT-3', "T12") and complementary (5'-dCTAACCCTAAC-3', "C-oligo") to the 3'-telomere overhang sequence were obtained from Midland Certified Reagent Co, Midland, TX. T12 and C-oligo were used as positive and negative controls, respectively.
Antibodies
Antibodies for TRF2, phospho-SAPK/JNK and total-SAPK/JNK were purchased from Cell Signaling (Danveres, MA). Anti-POT1 antibody was obtained from Abcam (Cambridge, MA).
Anti-β-actin antibody was purchased from Sigma-Aldrich (St. Louis, MO). Anti-G-quadruplex antibody was purchased from Absolute Antibody (Oxford, UK).
Cell Lines and Cell Culture
MM-AN cell line was obtained by explant culture (Puri et al., 2004 ) and maintained at 37°C in MEM (Thermo Fisher Scientific, Pittsburg, PA) supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic/antimycotic (Invitrogen, Carlsbad, CA).
Cell line STR profiling and authentication
DNA was extracted from MM-AN cells using QIAamp DNA mini kit (Qiagen, Valencia, CA), and STR analysis was performed by a third party, Genetica DNA Laboratories (a LabCorp brand; Burlington, NC) using the PowerPlexI 16HS amplification kit (Promega Corporation, Fitchburg, WI). The STR DNA profile of MM-AN cell was compared against known cell line 13 reference databases (e.g. ATCC, DSMZ) which was found "unique" with no contamination of any other cell line or mycoplasma.
G4 Formation and detection of G-quadruplexes Using NMR
To induce formation of G-quadruplex, 200-2000μM of oligonucleotides were diluted in TEbuffer and incubated at 95°C for 5min. The reaction was brought to 500mM NaCl or KCl and incubated at 60°C for 24h. The G4-structures were analyzed by loading 0.1μg of samples on a 20% non-denaturing gel. NMR experiments were performed for T-oligo, C-oligo, and positive control T12 (0.5mM) at pH-6.5 using a Bruker 800MHz AVANCE NMR Spectrometer at 283-295K. Full proton spectra of the annealed structures were recorded from 200-400nm using a scan rate of 100nm/min in potassium or sodium solutions.
Non-denaturing PAGE
Samples were prepared in a TBE-buffer containing 100mM NaCl or KCl at pH-7.0 and 1X Agarose loading dye, and then loaded (0.1μg) into a 20% polyacrylamide gel. Electrophoresis was performed at room temperature for 2.5h at 100V in TBE-buffer containing 100mM KCl or NaCl. The gel was stained with 1X SYBR Gold for 30min and DNA was detected by intercalation-induced fluorescence (excitation 495nm/emission 537nm) with a UVP ChemiDocIt TS2 imaging system.
MTT Cell Viability Assay
5,000 MM-AN cells/well were plated in replicates of six in 96-well plate. Cells were treated with T-oligo at concentrations (10-40μM) found to be nontoxic and maximally effective for 4h, after which MTT assay was performed as described previously . For Gquadruplex studies, cells were treated with G4-T-oligo (10-40μM) prepared in the presence of 500mM KCl. For JNK inhibition, cells were treated with 10μM SP600125 (Sigma-Aldrich, St. Louis, MO) for 96h in presence or absence of T-oligo. Percentage cell viability was determined relative to the control.
Nuclease Digestion
The SS and G4-T-oligo were incubated with DNase I (5U) for 0-90min at 37°C. After incubation at 60°C for 10min the reaction was quenched with 2.5mM EDTA. Samples were analyzed on a 20% non-denaturing gel which was stained in 1X SYBR gold for 40min and visualized on a transilluminator using the SYBR gold filter settings.
Immunoblotting
MM-AN cells were grown in MEM and were treated with 40μM T-oligo, C-oligo, or diluent for 24-72h, for lysates collection. For JNK inhibition, cells were treated with 10μM SP600125 for 24h in presence or absence of T-oligo. Immunoblotting was performed using antibodies against POT1, TRF2, total-JNK and p-JNK as described previously . Immunoblots were developed using ECL chemiluminescence kit (ThermoFisher Scientific, Rockford, IL).
Densitometry analysis was performed using NIH ImageJ software.
Real-Time PCR (qRT-PCR)
Total RNA was extracted using Qiagen Rneasy Mini Kit (Qiagen, Valencia, CA). qRT-PCR was performed using SuperScript III Platinum SYBR-Green One-Step Master-Mix on 7300 qRT-PCR system (Applied Biosystems, Carlsbad, CA). Specific hTERT primers-forward, 5'-GGCACACGTGGCTTTTCG-3'; reverse, 5'-GGTGAACCTCGTAAGTTTATGCAA-3' and GAPDH primers-forward, 5'-TTGCCAATGACCCCTTCA-3'; reverse, 5'-CGCCCCACTTGATTTTGGA-3' were used. The expression of hTERT gene was normalized with GAPDH levels. The fold changes were calculated using 2 (-ΔΔCt) method.
Immunofluorescence
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MM-AN cells (20,000 cells/well) were plated in eight chamber slides, allowed to adhere overnight. For G4 detection, cells were treated with 40μM FITC-T-oligo for 4h and incubated with a specific anti-G-quadruplex antibody (BG4) for 2h at room temperature. For visualization of TRF2 and POT1 upregulation, melanoma cells were treated with 40μM T-oligo for 12 hours and incubated with anti-TRF2 or anti-POT1 for 2 hours at room temperature. Cells were then incubated with Cy3 conjugated secondary antibody and images were captured using the Olympus Fv10i Fluoview confocal microscope.
Pull down assay
MM-AN cells (1. 2×10 6 ) were plated in 100mm tissue culture dishes and allowed to grow for 24h. Cells were treated with diluent, biotinylated-T-oligo (40μm), and biotinylated-C-oligo (40μm) for 6h and were lysed. Each cell lysate (1000μg) was incubated with 50μL of streptavidin magnetic beads (Thermofisher Scientific, Rockford, IL) for immunoprecipitation (IP) for 1h with constant rocking. The beads were washed twice with IP lysis buffer (Thermofisher Scientific, Rockford, IL) and once with distilled water. Proteins were eluted with 50µL of low pH Elution Buffer (Thermofisher Scientific, Rockford, IL) and 10μl of the eluant was analyzed with western blotting using anti-TRF2 and anti-POT1 antibodies.
Intracellular Uptake of FITC-labeled T-oligo Using FACS Analysis
The uptake of FITC-labeled SS and G4-T-oligo by MM-AN cells was assessed using FACS. The hTERT mRNA levels were determined by qRT-PCR. Data were normalized to GAPDH and expressed as fold change relative to the control. * p<0.05 (relative to T-oligo), * * p<0.01 (relative to diluent). 
